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ABSTRACT
Prion proteins (PrPs) cause prion diseases, such as
bovine spongiform encephalopathy. The conversion
of a normal cellular form (PrPC) of PrP into an
abnormal form (PrPSc) is thought to be associated
with the pathogenesis. An RNA aptamer that tightly
binds to and stabilizes PrPC is expected to block
this conversion and to thereby prevent prion
diseases. Here, we show that an RNA aptamer
comprising only 12 residues, r(GGAGGAGGAGGA)
(R12), reduces the PrPSc level in mouse neuronal
cells persistently infected with the transmissible
spongiform encephalopathy agent. Nuclear
magnetic resonance analysis revealed that R12,
folded into a unique quadruplex structure, forms a
dimer and that each monomer simultaneously binds
to two portions of the N-terminal half of PrPC, result-
ing in tight binding. Electrostatic and stacking inter-
actions contribute to the affinity of each portion. Our
results demonstrate the therapeutic potential of an
RNA aptamer as to prion diseases.
INTRODUCTION
Prion protein (PrP) is almost ubiquitously expressed and is
highly conserved in mammals. PrP exhibits two alternative
forms; a normal cellular form (PrPC), which is a soluble
a-helix-rich isoform, and an abnormal form (PrPSc), which
is an insoluble b-sheet-rich isoform and resistant to
cleavage by proteinase K (1,2). The details of the structure
of PrPSc and the mechanism underlying the conversion of
PrPC to PrPSc remain unknown. Prion diseases, also
known as transmissible spongiform encephalopathies
(TSEs), are invariably fatal neurodegenerative disorders
of mammals characterized by the accumulation of PrPSc
in the central nervous system (1–7). These disorders
include Creutzfeldt–Jakob disease in humans, bovine
spongiform encephalopathy in cattle and scrapie in sheep.
Considerable efforts have been made to develop a
compound that inhibits the accumulation of PrPSc in
prion-infected cells (8–17). An RNA aptamer that tightly
binds to PrPC is expected to stabilize PrPC and, thus, to
block the conversion to PrPSc. Therefore, such an RNA
aptamer may prevent prion diseases. However, attempts in
this context have been limited, and a structural basis of the
binding of an RNA aptamer to PrPC, which would facili-
tate such an application, has not been available. We
identified RNA aptamers that tightly bind to bovine
PrPC (bPrPC) (18,19). We revealed that the RNA
aptamer specifically binds to PrPC among various kinds
of proteins present in bovine brain homogenate (18).
Surprisingly, among the RNA aptamers, a short RNA
comprising only 12 residues, r(GGAGGAGGAGGA)
(R12), binds to bPrP strongly, the dissociation constant
being 8.5 109 M (18). We already reported the unique
quadruplex structure of R12 (20). Here, we have revealed
that R12 actually exhibits anti-prion activity on the basis
of the assay with mouse neuronal cells. Nuclear magnetic
resonance (NMR) analysis elucidates the structural basis
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high-performance liquid chromatography and desalted,
were purchased from Sigma-Aldrich and Nippon Seihun,
respectively. P1 (residues 25–35 of bPrP: NH2-
SKKRPKPGGGWN-COOH), P16 (residues 108–119:
NH2-GQWNKPSKPKTN-COOH) and mutant P16
peptides (K5A, K8A, K10A and W3A, respectively),
synthesized and purified by high-performance liquid chro-
matography, were purchased from Sigma-Aldrich or
Hipep Laboratories. Wild-type bPrP-N (residues 25–131)
and mutant bPrP-N (residues 25–131, 5WS) were
expressed with an Escherichia coli system and purified
using a reported protocol (21). Full-length bPrP
(residues 25–241) was purchased from Alicon.
Evaluation of anti-prion activity
The anti-prion activity of either R12 or D12 was examined
using mouse neuronal cells (GT1–7) persistently infected
with the human TSE agent (Fukuoka-1 strain), designated
as GT+FK, as described previously (14,16). The cells
were grown and maintained at 37C under 5% of CO2
in Dulbecco’s modified Eagle’s medium (Invitrogen) sup-
plemented with 10% of fetal bovine serum (Equitech-bio),
50 U/ml of penicillin G sodium and 50 mg/ml of strepto-
mycin sulphate (Invitrogen). Approximately 1.5 105 cells
were plated in each well of a six-well plate, and treatment
with either R12 or D12 was started 15 h later. R12
(0.25mM) and D12 (0.35mM) were dissolved in a buffer
solution containing 10mM of K-phosphate (pH 6.2) and
100mM of KCl, respectively. Either 80 ml of the R12
solution or 57 ml of the D12 solution was added to 2ml
of the medium, with the final concentration of both R12
and D12 being 10 mM. As a control, either 80 or 57 ml of
the buffer solution was added to the medium. For the
conditions with an RNase inhibitor, 800U of RNasin
(Promega) was added to the medium 5min before the
addition of the R12 solution. As a reference nucleic acid,
U12 was added to the medium to the final concentration
of 10 mM after the addition of the RNase inhibitor. After
72 h of treatment, cells were lysed in 150 ml of 1 Triton
X-100-deoxycholate lysis buffer [150 mM of NaCl, 0.5%
of Triton X-100, 0.5% of sodium deoxycholate, 50mM of
Tris–HCl (pH 7.5)], and the supernatant was collected.
Samples were digested with 20 mg/ml of proteinase K for
30min at 37C. Western blotting for PrPSc was performed
as described previously (22). As the primary antibody, PrP
M-20 antibody (Santa Cruz Biotechnology) was used to
detect PrPSc. The signals were visualized with Super-Signal
(Pierce Biotechnology) and scanned using a LAS-1000 UV
mini analyser (Fuji Film). The density of PrPSc in each
solution was measured and compared with that in the
control treated with just the buffer solution. Each assay
with either R12 or D12 was repeated eight times.
Microchip electrophoresis assay
A Hitachi SV1210 microchip CE system (Hitachi
Electronics Engineering) was used for microchip electro-
phoresis (ME) analysis, as described previously (19,20).
R12 was incubated in the binding buffer comprising
20mM of Tris–HCl (pH 7.5) and 10mM of KCl under
the re-folding conditions: 90C for 2min, 72C for 5min,
55C for 5 min and 37C for 2 min and then kept at 25C.
After the addition of 10 nM of Cy5-20-deoxyuridine 50-
triphosphate (dUTP) (Amersham Biosciences), the
internal standard, R12 (100 nM), was incubated with a
peptide (0 and 100 mM) in the binding buffer of 10 ml for
15 min and was then analysed by ME (20). The observed
peak intensity of R12 was divided by the peak intensity of
the internal standard, which gave the relative peak inten-
sity. The relative peak intensity value of R12 was
normalized by dividing by the relative peak intensity of
R12 in the absence of peptide, which gave the normalized
peak intensity. The relative binding of R12 was defined as
1 (the normalized peak intensity) and was calculated for
the wild-type and mutant P16 peptide (Figure 3H).
Filter binding assay
The 50-end g-32P-labelled R12 (<10 nM) was mixed with
varying concentrations of either a peptide or protein to
give a total volume of 25 ml in a solution comprising
20mM of Tris–HCl (pH 7.5) and 10mM of KCl. After
20min incubation, each mixture was passed through a
nitrocellulose filter and washed with 500 ml of the
solution. The amount of bound RNA was measured
with BAS 2500 (Fuji Film), and binding activities were
calculated as the percentage of input RNA in the
peptide- or protein-RNA complex retained on the filter.
We determined the dissociation constant (Kd) using
GraphPad PRISM and non-linear regression curve
fitting, and a one site-binding hyperbola equation {RNA
binding (%)=Bmax (peptide or protein)/[Kd+(peptide
or protein)], where Bmax is the maximum bound at the
saturating peptide or protein concentration} (18).
Titration and structure determination
In titration experiments, either P1, P16 or bPrP-N(25–131,
5WS) was added step-by-step to R12 in a solution
comprising 10mM of K-phosphate (pH 6.2) and 10mM
of KCl at 30C. Structural determination of the R12:P16
complex was carried out under the same conditions. NMR
spectra, nuclear overhauser effect spectroscopy (NOESY),
total correlation spectroscopy (TOCSY), double-quantum
filtered correlation spectroscopy (DQF-COSY), 1H-13C
heteronuclear single quantum coherence (HSQC) and
heteronuclear multiple bond coherence with jump and
return solvent suppression (JRHMBC) were recorded
with Bruker DRX600 and DRX800 spectrometers
equipped with a cryoprobe. Distance and dihedral con-
straints were obtained as described previously (20)
(Supplementary Table S1). Structural calculations were
carried out using these constraints and a simulated anneal-
ing protocol supplied with XPLOR-NIH v. 2.26 (23,24),
as described previously (20,25). The R12:P16 complex
comprises two R12 monomers and two P16 monomers,
as explained in the main text. Ten final structures were
selected from 100 calculations on the basis of the criterion
of the smallest residual energy term. The statistics are
shown in Supplementary Table S1. The final ensemble of
ten structures of the R12:P16 complex has 13.1 and 86.9%
in the most favoured and additional allowed regions, re-
spectively, for the P16 peptide. Molecular images were
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generated with MOLMOL (http://www.mol.biol.ethz.ch/
groups/wuthrich_group/software) and University of
California, San Francisco (UCSF) Chimera (http://www
.cgl.ucsf.edu/chimera/).
RESULTS
Anti-prion activity of R12
The anti-prion activity of R12 has been examined using
mouse neuronal cells (GT1-7) persistently infected with
the human TSE agent (Fukuoka-1 strain), designated as
GT+FK. R12 was found to inhibit the PrPSc formation in
GT+FK at 10 mM (second and third lanes in Figure 1).
R12 reduced the PrPSc level to 65.0% of that in the control
(Table 1, P< 0.001). When an RNase inhibitor, RNasin,
was added to the medium, R12 reduced the PrPSc level
even more, that is, to 49.4% (eighth and ninth lanes in
Figure 1 and Table 1, P< 0.001). The observed difference
between in absence and presence of an RNase inhibitor
(Table 1, P< 0.05) is supposed to be because of the
repressed degradation of R12 in the medium caused by
the RNase inhibitor. No reduction of the PrPSc level was
observed for U12 even in the presence of the RNase
inhibitor (Table 1). Therefore, the reduction is specific to
R12. The DNA version of R12, d(GGAGGAGGAGGA)
(D12), also tightly binds to bPrPC, the dissociation
constant being 6.4 108 M (18). D12 reduced the PrPSc
level to 75.5% (fifth and sixth lanes in Figure 1 and
Table 1, P< 0.01), although its inhibitory effect is less
than that of R12. Thus, we have demonstrated that R12,
and also D12 to a lesser extent, exhibits anti-prion activity
towards cells persistently infected with the TSE agent.
Structure of R12 in complex with the binding
peptide of bPrP
Then, we tried to elucidate the structural basis of the tight
binding of R12 to bPrPC. The structure of bPrPC is avail-
able (21); the C-terminal half of bPrPC is composed of
three a-helices and two short b-strands, whereas the
N-terminal half is basically flexible and disordered. Two
portions of bPrP were identified as binding sites for R12
by epitope mapping using ME (20). They are residues
25–35 (SKKRPKPGGGWN, designated as P1) and
108–119 (GQWNKPSKPKTN, designated as P16) of
bPrP. Both binding sites commonly include three Lys
residues and one Trp residue. The dissociation constants
for the R12:P1 and R12:P16 complexes are 1.7 105 M
and 1.0 105 M, respectively, being similar to each
other. Chemical shift perturbation of each imino proton
of R12 was traced during the course of titration with P16
(Figure 2A). The perturbation reached a plateau when the
P16/R12 molar ratio was 3.0. Thus, the perturbation at
each molar ratio was divided by the perturbation at the
molar ratio of 3.0 and defined as a normalized perturb-
ation for each imino proton. Then, the normalized per-
turbation was plotted against the P16/R12 molar ratio
(Figure 2B). The initial slope of the plot almost coincides
with that expected for the formation of the R12:P16=1:1
complex. The deviation of the experimental points from
the initial slope for larger P16/R12 molar ratios is ration-
ally understood, when the dissociation constant of
1.0 105 M and the concentrations of P16 and R12
applied for each point are taken into account, which
also supports the formation of the 1:1 complex. As
described later in the text, R12 forms a dimer in the
complex. Therefore, the complex should comprise two
R12 monomers and two P16 monomers.
Table 1. Anti-prion activities of R12 and D12*
PrPevitaleRtnemtaerT Sc level (%) 
001lortnoC
R12 65.0 ± 9.3
R12 + RNase inhibitor 49.4 ± 17.4 
U12 + RNase inhibitor 98.8 ± 5.8 
D12 75.5 ± 17.0 
*Each assay was repeated eight times. 
















































Figure 1. Anti-prion activity of r(GGAGGAGGAGGA) (R12) and
d(GGAGGAGGAGGA) (D12). Western blotting of PrPSc in
GT+FK cells after treatment with either 10 mM R12 or D12. Two
independent experiments, #1 and #2, are shown. The control was
treated with just the buffer solution. The treatment with R12 was
also performed in the presence of an RNase inhibitor, RNasin.
Molecular mass markers are shown at the left.
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The imino proton spectrum of the R12:P1 complex is
similar to that of the R12:P16 complex (Figure 2C). In
fact, the chemical shift perturbation of R12 on binding
of P1 is similar to that on binding of P16, except for
that for a G11 residue (Supplementary Figure S1). This
suggests that the interaction of R12 with P1 is similar to
that with P16, although some difference in interaction
and/or structure may be present around G11. The
similar dissociation constants obtained for the R12:P1
and R12:P16 complexes are consistent with this idea.
Thus, to elucidate the interaction of R12 with bPrP, we
have determined the structure of R12 in a complex with
P16 as a representative.
The resonance assignments of R12 in the R12:P16
complex were made (Supplementary Figure S2A and B)
in the same way as reported for free R12 (20). Then, the
G:G:G:G tetrad and G(:A):G:G(:A):G hexad structures
were identified on the basis of the observation of charac-
teristic NOESY cross peaks (Figure 2D and E), as for free
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Figure 2. NMR analysis of the R12:P16 complex. (A) The imino proton spectra of R12 in the course of the titration with P16, the assignments
being indicated by residue numbers. The numbering of R12 is G1G2A3G4G5A6G7G8A9G10G11A12. The molar ratio is indicated at the left.
(B) Normalized chemical shift perturbation for each imino proton of R12 in the course of the titration with P16. (C) Imino proton spectra of R12,
the R12:P1 complex and the R12:P16 complex with the assignments. (D and E) The G:G:G:G tetrad (D) and G(:A):G:G(:A):G hexad (E) planes.
The observed NOESY cross peaks and hydrogen bonds are indicated by solid and dotted lines, respectively. (F and G) Intermolecular NOESY cross
peaks observed for the K5 (F) and W3 (G) residues of P16, respectively. The numbering of P16 is G1Q2W3N4K5P6S7K8P9K10T11N12.
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adenosine residue is larger than 4.5 A˚ for any conform-
ation (26). Therefore, observation of strong NOESY
cross peaks between H2 and H10 for an A3 residue and
also for an A9 residue (Supplementary Figure S2C) is an
indication that R12 in the complex forms a dimer, as free
R12 does (20). The dimer formation of R12 in the complex
was supported by many other NOESY cross peaks as well.
Resonance assignments of P16 in the R12:P16 complex
were also made (Supplementary Figure S2D) using a
standard protocol (26). Then, many intermolecular
NOESY cross peaks were identified on the basis of the
resonance assignments (Figure 2F and G).
The structure of the R12:P16 complex comprising two
R12 monomers and two P16 monomers was determined
on the basis of distance and dihedral angle constraints
(Figure 3). The structure of the complex reveals the
origin of the high affinity. Three Lys residues of P16 are
involved in the electrostatic interactions with the phos-
phate groups of R12; K5 of P16 with G5 of R12, K8
with G11 and K10 with A9, respectively (Figure 3C–E
and G). The average of the closest distance for 10 final
structures between an Hz atom of the Lys residue and an
oxygen atom of a phosphate group is 3.71 A˚, 3.67 A˚ and
4.65 A˚, respectively. In addition, a stacking interaction
was found between the rings of W3 of P16 and G8 of
R12 (Figure 3F and G). These interactions were biochem-
ically confirmed by ME using mutant P16 peptides. A
decrease in affinity to R12 was observed for four mutant
P16 peptides in which either K5, K8, K10 or W3 was
replaced by an alanine residue, respectively (Figure 3H).
Overall architecture responsible for tight trapping
of bPrP by R12
As described earlier in the text, R12 is suggested to
interact with P1 in a similar way as it does with P16, the
interaction involving three lysine residues and one trypto-
phan residue, which both P1 and P16 commonly possess.
Therefore, it is likely that in the R12:bPrP complex, one
monomer of the R12 dimer interacts with P1 and the other
monomer with P16 (Figure 4A). To confirm this, a titra-
tion experiment on the N-terminal region of bPrP,
bPrP-N(25–131), which contains the two binding sites,
P1 (residues 25–35) and P16 (residues 108–119), was per-
formed. bPrP-N(25–131) tightly binds to R12. The dis-
sociation constant for the R12:bPrP-N(25-131) complex
was 2.1 108 M, which is roughly comparable with
that for the R12: full-length bPrP(25–241) complex,
8.5 109 M. Unfortunately, precipitation was observed
in the course of the titration with bPrP-N(25–131),
probably because of the low solubility of the complex,





























































































































Figure 3. The structure of the R12:P16 complex. (A) NMR structure
ensemble of the R12:P16 complex. The two R12 monomers are
coloured red and blue, respectively, phosphate groups being coloured
green. The two P16 monomers are coloured magenta and purple, re-
spectively. (B) The representative structure with the lowest energy. The
chains connecting the C30 and C40 atoms of each R12 monomer are
indicated by red and blue tubes, respectively. The chains connecting the
Ca atoms of each P16 monomer are indicated by magenta and purple
tubes, respectively. The pairs K5 and G5, K8 and G11, K10 and A9
and W3 and G8 are coloured pink, orange, green and blue, respectively.
Figure 3. Continued
(C–F) Close-up views of intermolecular interactions between K5 of P16
and G5 of R12 (C), K8 and G11 (D), K10 and A9 (E) and W3 and G8
(F), respectively. (G) Summary of interactions. The electrostatic inter-
actions between K5 of P16 and G5 of R12, K8 and G11 and K10 and
A9 and the stacking interaction between W3 and G8 are indicated.
(H) The relative binding is shown for wild-type P16 and four mutant
P16, in which either K5, K8, K10 or W3 was replaced by an alanine
residue, respectively.
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five tryptophan residues of the octapeptide repeat region
of bPrP-N(25–131), Trp 60, Trp 68, Trp76, Trp 84 and
Trp 92 were replaced by serine residues, resulting in
bPrP-N(25–131, 5WS). It should be noted that the tryp-
tophan residues that are involved in P1 and P16 and
interact with R12 are Trp 34 and Trp 110, respectively,
and that they are not replaced. In fact, it was found that
bPrP-N(25–131, 5WS) also tightly binds to R12, the dis-
sociation constant being 5.5 108 M, which is almost
comparable with that for wild-type bPrP-N(25–131).
Precipitation was not observed during the titration with
bPrP-N(25–131, 5WS). The chemical shift perturbation of
each imino proton of R12 in the course of the titration
with bPrP-N(25–131, 5WS) was traced. The perturbation
reached a plateau when the bPrP-N/R12 molar ratio was
0.56. Thus, the perturbation at each molar ratio was
divided by the perturbation at the molar ratio of 0.56
and defined as a normalized perturbation for each imino
proton. The normalized perturbation was plotted against
the molar ratio (Figure 4B). The initial slope of the plot
almost coincides with that expected for the formation of
the R12:bPrP-N(25–131, 5WS)=1:0.5 complex. Because
of the dimer formation of R12, this indicates that the
complex comprises two R12 monomers and one
bPrP-N(25–131, 5WS) molecule. This is consistent with
the idea aforementioned that one monomer of the R12
dimer interacts with P1 of bPrP and that the other
monomer with P16 of the same bPrP molecule
(Figure 4A). The deduced simultaneous binding of the
R12 dimer with two binding sites of a single bPrP
molecule must also contribute to the high affinity
because the double binding could ideally increase the
affinity by as much as the square of the binding
constant if each interaction is perfectly achieved, respect-
ively (27).
Only one resonance is observed for each imino proton
of R12 in complex with bPrP-N(25–131, 5WS)
(Figure 4C), although two imino protons of each
monomer of R12 could potentially be non-equivalent in
the complex. This observation suggests that each R12
monomer switches binding site, P1 and P16 and vice
versa, in fast exchange regime on an NMR time scale. It
is consistent with this idea that each imino proton reson-
ance of R12 in the complex with bPrP-N(25–131, 5WS)
appears between the corresponding resonances of R12 in
the complex with P1 and that with P16, except for a G11
residue (Figure 4C).
DISCUSSION
We have demonstrated that R12 reduces the PrPSc level of
mouse neuronal cells persistently infected with the human
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Figure 4. Overall architecture of tight trapping of bPrP by R12. (A)
Overall architecture of the complex between bPrP and R12. The tetrad
and hexad planes of R12 are indicated by a square and a hexagon,
respectively. The lysine and guanosine residues involved in the electro-
static interaction are coloured orange, and the tryptophan and guano-
sine residues involved in the stacking interaction are coloured blue,
respectively. The structure of the C-terminal region of bPrP is drawn
on the basis of the coordinates under accession number 1DX0 in the
Figure 4. Continued
Protein Data Bank (21). (B) Normalized chemical shift perturbation for
each imino proton of R12 in the course of the titration with
bPrP-N(25–131, 5WS). (C) Imino proton spectra of the R12:P1
complex, the R12:P16 complex and the R12:bPrP-N(25–131, 5WS)
complex with the assignments.
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and stabilizes PrPC, blocked the conversion into PrPSc.
The amino acid identity and similarity between the
bovine and mouse PrPs are high, 89 and 93%, respect-
ively. Moreover, the two sites of bPrP that are responsible
for binding of R12 are located in the N-terminal unfolded
region, as described later in the text, and the amino acid
sequences of these two sites are almost identical for bovine
and mouse PrPs. Therefore, it is likely that R12 selected as
to bPrP also functioned for mouse PrP. Moreover, the
amino acid sequences of these two sites for human PrP
are also almost identical to those for bovine and mouse
PrPs. There is the possibility that R12 may function for
human PrP.
Recently, it has been reported that the segment 100–104
of mouse PrPC plays a key role in the conversion after
binding to mouse PrPSc (28). This segment corresponds
to the 112–116 segment of bPrP, which is actually the
K5 to P9 segment of a P16 peptide used in this work.
Therefore, our observation that R12, which tightly binds
to P16 (and P1) of bPrP, reduces the PrPSc level is con-
sistent with this report.
It has been revealed this time that the unique R12 struc-
ture observed in a free form is preserved also in a complex
form with bPrP. The structure determination of the
complex with the binding peptide of bPrP has provided
the detailed information on the interaction. It has been
identified for the first time that the phosphate groups of
G5, A9 and G11 of R12 are involved in the electrostatic
interaction. Pairing for the interaction with one of three
Lys residues of P16 has also been found. The structure has
also revealed that the guanine base that makes stacking
interaction with a Trp residue of P16 is that of G8 of R12.
These kinds of information cannot be obtained without
the structure determination of the complex. Then, the high
affinity of R12 has been attributed to the simultaneous
dual binding. For therapeutic application of R12 in
future, chemical modification of either sugars or
backbone may be required to increase the RNase resist-
ance. In this case, however, the chemical modifications on
R12 should not interfere with the R12–PrP interactions.
The information on the interactions obtained from both
the detailed complex structure and the overall architecture
must be helpful to determine the position and the kind of
modification.
We previously reported the structure of D12 (29).
D12 forms a similar quadruplex structure to R12. In
addition to the common G:G:G:G tetrad, the
G(:A):G(:A):G(:A):G heptad is formed for the D12
quadruplex, instead of the G(:A):G:G(:A):G hexad for
the R12 quadruplex. D12 also forms a similar dimer struc-
ture to R12, although the direction of the dyad axis differs
between the D12 and R12 dimers. Therefore, it is likely
that D12 interacts with bPrP in a similar way to R12.
Some structural differences between the R12 and D12
quadruplexes may be responsible for the difference in
affinity to bPrP. The lower anti-prion activity of D12 is
supposed to be because of the lower affinity to and less
stabilization of bPrPC. Nonetheless, the finding of
anti-prion activity for D12 is still interesting.
Compounds that inhibit the accumulation of PrPSc in
prion-infected cells have been developed. Among them,
GN8 binds to the hot spots in the C-terminal region of
PrP (14), and a lysosomotropic agent, quinacrine, to the
third helix in the C-terminal region of PrP (13). Pentosan
polysulphate is reported to bind to the octapeptide repeats
in the N-terminal region of PrP (15). Recently, Congo red
was reported to bind to the lysine residue in the groove
formed in Heterokaryon incompatibility protein s
(HET-s) amyloid (17). The site and mode of interaction
of R12 with PrP are different from those of these com-
pounds. Therefore, the modulation of PrP conformational
conversion by R12, and probably by D12 also, would be
distinct from that by pre-existing anti-prion agents.
Recently, PrPC has also been suggested to be a mediator
of the amyloid-b-oligomer-induced synaptic dysfunction
linked to Alzheimer’s disease (30). It was revealed that
anti-PrP antibodies prevent amyloid-b-oligomer binding
to PrPC, and that the antibodies rescue synaptic plasticity
in hippocampal slices from oligomeric amyloid-b. An
RNA aptamer also tightly binds to PrPC like antibodies;
hence, the RNA aptamer may also rescue synaptic plasti-
city by preventing amyloid-b-oligomer binding to PrPC.
Therefore, an RNA aptamer for PrPC may have thera-
peutic potential not only for prion diseases but also for
Alzheimer’s disease.
In conclusion, we have demonstrated that a short RNA
aptamer for PrPC that comprises only 12 residues, R12,
exhibits anti-prion activity in mouse neuronal cells persist-
ently infected with the TSE agent. There is the possibility
that R12 is also effective for bovine spongiform encephal-
opathy. The structural basis of the tight binding of R12 to
PrPC has been elucidated. These findings may be used to
develop RNA aptamer-based drugs against the prion and
Alzheimer’s diseases.
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